SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
MorphoSys AG (MOR)
An SI Board Since January 2000
Posts SubjectMarks Bans
421 15 0
Emcee:  michael_f_murphy Type:  Unmoderated
Introduction Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
371About Roche, Gantenerumab and Milestones and Royalities: CEO Moroney said a lotGermanecki-6/13/2012
370The program is discussed in siliconinvestor.com and siliconinvestor.com (check tDewDiligence_on_SI16/11/2012
369Hi Dew, do you have a link or url to the discussion?Germanecki-6/11/2012
368There’s some discussion of this early-AD program on iHub. It’s been under the raDewDiligence_on_SI16/7/2012
367Potentially pivotal study: MorphoSys receives clinical milestone payment from RoGermanecki-6/7/2012
366Update on Gantenerumab for early AD: siliconinvestor.comDewDiligence_on_SI-6/6/2012
365 AbD Serotec to Launch Panel of HuCAL Anti-Drug Antibodies Supporting the DevelGermanecki-5/23/2012
364 MorphoSys and Xencor Complete Enrollment in MOR208 (Xmab5574) Phase 1 Trial inGermanecki-5/23/2012
363 MorphoSys to Present MOR208 Preclinical Combination Therapy Data at ASCO MeetiGermanecki-5/23/2012
362 MorphoSys AG Reports Results for the First Quarter of 2012 May 04, 2012 / 7:Germanecki-5/23/2012
361On the Morphosys call they said the program has been stopped in the oncology inghmm-5/4/2012
360 MorphoSys to Start Share Buy-Back Program April 02, 2012 / 7:30 am, CET MGermanecki-4/2/2012
359 MorphoSys Announces Clinical Milestone from Strategic Alliance March 28, 201Germanecki-4/2/2012
358AbD Serotec Expands Range of HuCAL Antibodies Used in Clinical Diagnostic Kits.MGermanecki-4/2/2012
357 MorphoSys Completes Enrollment in MOR103 Phase 1b/2a Rheumatoid Arthritis TriaGermanecki-4/2/2012
356 MorphoSys AG Reports Record Results for Fiscal Year 2011 March 01, 2012 / 7:Germanecki-4/2/2012
355 MorphoSys Signs Three-Year Protein Engineering Alliance on Slonomics TechnologGermanecki-4/2/2012
354Seems the IPF MAB was too toxic. clinicaltrials.govghmm-3/13/2012
353 MorphoSys Strengthens Patent Position on MOR202 Program January 23, 2012 / 7Germanecki-1/24/2012
352MorphoSys Initiates Phase 1b Clinical Trial with MOR103 in Patients with MultiplGermanecki-12/21/2011
351 MorphoSys and Novozymes Sign Long-Term Alliance on Slonomics® Technology Germanecki-12/15/2011
350Take a look on this: morphosys.com Proprietery pipeline MOR103: MOR103 is thGermanecki-12/15/2011
349Seems like an interesting company. Small valuation, huge pipeline, large number mcbio-12/8/2011
348[graphic]Germanecki-12/8/2011
347 MorphoSys to Receive Milestone Payment for CNTO 1959 Phase 2 Program DecembeGermanecki-12/8/2011
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News